Ribociclib - Findings from the MAINTAIN study

Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treatment and Received Ribociclib After Previous CDK4/6 Inhibitor and Different Endocrine Therapy

the full article is availabel at ESMO Oncology News (Link)